How effective are disease modifying drugs in treating multiple sclerosis?
Data access has been approved for the first study designed specifically to investigate both long-term effectiveness and potential adverse drug effects of the full spectrum of disease modifying drugs (DMDs) used to treat multiple sclerosis (MS).
Data access has been approved for Phase II of a research project which aims to reduce the incidence of adverse drug events in Canada.
Data access has been approved for Phase II of a research project which aims to reduce the incidence of adverse drug events in Canada.